Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company ...

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Sun Pharma is set to acquire Checkpoint Therapeutics for $355 million, enhancing its specialty portfolio with UNLOXCYT, an ...

Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for ...

Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and ...

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This ...

The acquisition will bolster Sun Pharma’s onco-dermatology portfolio, adding Checkpoint’s recently FDA-approved cancer drug, UNLOXCYT (cosibelimab-ipdl), to its pipeline. The deal, expected to ...

FDA-approved Unloxcyt (cosibelimab-ipdl) for metastatic or locally advanced cSCC in patients unsuitable for curative treatment. The new Benzinga Rankings show you exactly how stocks stack up ...